Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 257 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in... March 10, 2026 Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... January 5, 2023 New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo... September 13, 2019 Load more HOT NEWS We have a Deal: What does the new UK-EU relationship mean... Political Interests Are A Major Adversary in the War on Women Our COVID-19 Response: How We’re Supporting Frontline Workers At Revolution Foods Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient...
